- Home
- LXRX vs DERM Comparison
LXRX vs DERM Comparison
Compare LXRX & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- DERM
- Stock Information
- Founded
- LXRX 1995
- DERM 2014
- Country
- LXRX United States
- DERM United States
- Employees
- LXRX N/A
- DERM N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- DERM Health Care
- Exchange
- LXRX Nasdaq
- DERM Nasdaq
- Market Cap
- LXRX 124.4M
- DERM 140.0M
- IPO Year
- LXRX 2000
- DERM 2021
- Fundamental
- Price
- LXRX $0.51
- DERM $6.25
- Analyst Decision
- LXRX Buy
- DERM Strong Buy
- Analyst Count
- LXRX 4
- DERM 2
- Target Price
- LXRX $3.67
- DERM $10.00
- AVG Volume (30 Days)
- LXRX 32.2M
- DERM 103.6K
- Earning Date
- LXRX 05-01-2025
- DERM 05-12-2025
- Dividend Yield
- LXRX N/A
- DERM N/A
- EPS Growth
- LXRX N/A
- DERM N/A
- EPS
- LXRX N/A
- DERM N/A
- Revenue
- LXRX $31,081,000.00
- DERM $56,134,000.00
- Revenue This Year
- LXRX N/A
- DERM $29.83
- Revenue Next Year
- LXRX $63.36
- DERM $54.88
- P/E Ratio
- LXRX N/A
- DERM N/A
- Revenue Growth
- LXRX 2481.48
- DERM N/A
- 52 Week Low
- LXRX $0.28
- DERM $3.20
- 52 Week High
- LXRX $2.45
- DERM $7.29
- Technical
- Relative Strength Index (RSI)
- LXRX 53.30
- DERM 53.65
- Support Level
- LXRX $0.48
- DERM $5.98
- Resistance Level
- LXRX $0.60
- DERM $6.40
- Average True Range (ATR)
- LXRX 0.09
- DERM 0.62
- MACD
- LXRX 0.01
- DERM -0.06
- Stochastic Oscillator
- LXRX 42.86
- DERM 36.97
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.